INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 10/17/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 10/16/23
Cassava Sciences slumps after leaked report claims 'egregious misconduct' over Alzheimer's drugProactive Investors • 10/13/23
Cassava shares plummet after investigation accuses researcher of ‘egregious misconduct'Market Watch • 10/13/23
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the PressGlobeNewsWire • 10/13/23
Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD BetSeeking Alpha • 10/11/23
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer's DiseaseGlobeNewsWire • 10/02/23
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer's DiseaseGlobeNewsWire • 09/18/23
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer's DiseaseGlobeNewsWire • 09/13/23